VolitionRx shares surge 13.50% intraday after scheduling Q2 2025 earnings conference call and business update.

Volitionrx (VNRX) surged 13.50% intraday following the announcement of its scheduled Second Quarter 2025 Earnings Conference Call and Business Update on August 8, 2025, alongside insider buying activity. A director acquired 78,125 shares on August 7, signaling confidence in the company’s prospects. The earnings call, typically associated with potential positive business updates or financial results, likely drove investor optimism, while the insider purchase reinforced perceptions of management’s conviction. These events aligned with the stock’s sharp intraday rally, reflecting market anticipation of favorable developments.